"Hydroxamic Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of weak acids with the general formula R-CONHOH.
| Descriptor ID |
D006877
|
| MeSH Number(s) |
D02.092.570.394 D02.241.511.372
|
| Concept/Terms |
Hydroxamic Acids- Hydroxamic Acids
- Acids, Hydroxamic
- Hydroxamic Acid
- Acid, Hydroxamic
|
Below are MeSH descriptors whose meaning is more general than "Hydroxamic Acids".
Below are MeSH descriptors whose meaning is more specific than "Hydroxamic Acids".
This graph shows the total number of publications written about "Hydroxamic Acids" by people in this website by year, and whether "Hydroxamic Acids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 2 | 3 |
| 2005 | 1 | 1 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 3 | 3 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 4 | 5 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 2 | 3 |
| 2016 | 3 | 0 | 3 |
| 2017 | 2 | 0 | 2 |
| 2020 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxamic Acids" by people in Profiles.
-
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. Neuro Oncol. 2022 04 01; 24(4):655-664.
-
Copper oxide nanoparticles induce anticancer activity in A549 lung cancer cells by inhibition of histone deacetylase. Biotechnol Lett. 2018 Feb; 40(2):249-256.
-
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018.
-
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood. 2014 Oct 23; 124(17):2687-97.
-
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 2014 Jul 30; 5(14):5637-50.
-
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014 Jul; 146(1):145-52.
-
Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity. PLoS One. 2014; 9(1):e87203.
-
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther. 2014 May; 13(5):1142-54.
-
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013 Dec 15; 19(24):6882-90.
-
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013 Aug; 162(3):326-35.